gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · LGVNHealthcarePharmaceuticals

Longeveron Inc. Common Stock (LGVN)

$1.780.00%
Close Nov 4, 2026 · split-adjusted
Oct 30, 2026$1.67▼ 79.89% in range
Nov 3, 2025Low $1.39 · High $70.33Oct 30, 2026
What changed · written from our data
As of Nov 4, 2026

Longeveron closed at $1.78 on Nov 4, unchanged, 97.5% below its 52-week closing high. Volume of 61.4K shares was 0.82× its 20-day average (close to normal).

Split-adjusted performance: -24.3% over one month, -79.6% over six months, -78.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $287K, down 9.2% from a year earlier, with a net margin of -2116.0%.

Short interest was 73.2K shares at the Oct 15 settlement, down 31.5% from the prior report (2.8% of float, 1.0 days to cover).

Market cap$5.7M3.2M shares
Revenue · quarter$287.0K−9.2% YoY
Diluted EPS$-1.90—
P/E · TTM—P/S 4.8×
Net margin-2,116.0%Gross 63.4%
Dividend yieldNone
52-week range1.39 – 70.33−97.5% from high
Volume61.4K0.82× 20-day avg
Volatility · 60d708.8%Annualised
Short % of float2.8%1.0 days to cover
Net cash$10.1MCash $10.1M
Next earnings—Not scheduled
Split-adjusted performance
1W 0.0%1M −24.3%3M −77.0%6M −79.6%YTD −64.8%1Y −78.6%3Y −99.1%5Y −99.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum7
Revenue growth33
Net margin12
Value (low P/E)—
Size10

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short73.2K−31.5% vs prior
Days to cover1.0Settled Oct 15
% of float2.8%
Short vol. 10d52.5%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
LGVNLongeveron$1.780.00%−79.6%−9.2%−2116.0%—$5.7M
ACXPAcurx Pharmaceuticals$1.03+0.98%−50.7%———$5.6MCompare
SCNXScienture Holdings$3.42−0.87%−65.0%—−821.3%—$5.6MCompare
PULMPulmatrix$1.52+14.29%+11.8%———$5.6MCompare
PCSAProcessa Pharmaceuticals$1.94−0.26%−29.6%———$5.4MCompare
IMNNImunon$0.9070+0.78%−66.5%———$5.1MCompare
CNSPCNS Pharmaceuticals$4.34−4.62%−37.1%———$6.3MCompare
APREAprea Therapeutics$0.5052−1.90%−39.4%−100.0%——$6.4MCompare
SKYESkye Bioscience$1.14−6.56%−83.3%———$5.0MCompare

News about Longeveron

All news →

No recent articles focused on Longeveron. 3 articles mention it in passing.

Quick answers

What does Longeveron do?
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel.
What is LGVN's market cap?
$5.67M, based on the Nov 4 close of $1.78.
Does Longeveron pay a dividend?
No regular cash dividend has been paid in the last year.
How much of LGVN is sold short?
73.2K shares, 2.8% of float, as of Oct 15, 2026.
What sector is LGVN in?
Healthcare, in the Pharmaceuticals industry.

About Longeveron

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

HQ: Miami, FL38 employeesListed Feb 12, 2021longeveron.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology